Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. Co. is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Co. are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Co.'s preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. We show 7 historical shares outstanding datapoints in our PLUR shares outstanding history coverage, used to compute PLUR market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing PLUR market cap history over the course of time is important for investors
interested in comparing PLUR's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of PLUR versus a peer is one thing; comparing
PLUR market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like PLUR can fluctuate over the course of history.
With this page we aim to empower investors researching PLUR by allowing them to research the PLUR market cap history. |
Free PLUR Email Alerts:
Video: The Importance of Market Cap
